SAB Biotherapeutics (SABS) Total Debt (2020 - 2025)

SAB Biotherapeutics' (SABS) quarterly Total Debt came in at $541644.0 in Q4 2022, up 214.84% on a QoQ basis from $172037.0 in Q4 2020.

Analysis

SAB Biotherapeutics (SABS) Total Debt (2020 - 2025) Analysis & Trends

SAB Biotherapeutics (SABS) has 2 years of Total Debt data on file, last reported at $541644.0 in Q4 2022.

Quarterly Total Debt changed N/A year-over-year to $541644.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $541644.0 (changed N/A YoY) and the FY2022 annual result came in at $541644.0, changed N/A from the prior year.
Total Debt rose to $541644.0 in Q4 2022, from $172037.0 in the prior quarter.
In the past five years, Total Debt ranged from a high of $541644.0 in Q4 2022 to a low of $172037.0 in Q4 2020.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	591.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	1.07 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	9.34 Bn
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	546.77 Mn
10	SAB Biotherapeutics	296.68 Mn	296.68 Mn	-	-

Historic Data

Download Data